South Africa began rolling out Lenacapavir, a twice-yearly injectable HIV prevention drug, on June 5, 2026 [1], [3].
The initiative aims to curb the HIV epidemic and strengthen national prevention efforts following U.S. aid cuts that occurred approximately 18 months ago [4].
Health Minister Aaron Motsoaledi said the rollout will target 360 health facilities located in high-burden districts [2]. The drug represents a shift in prevention strategy because it requires only two injections per year [1].
President Cyril Ramaphosa said the move is a defining moment in the country's fight against HIV/AIDS [5]. The administration views the availability of the medication as a critical turning point for the national health response [6].
Officials are prioritizing districts with the highest infection rates to maximize the impact of the limited initial rollout. The transition to long-acting injectables is expected to reduce the burden on patients who previously relied on daily medication regimens.
"This is a defining moment in our fight against HIV/AIDS," Ramaphosa said [5].
"We will roll out Lenacapavir from 5 June to 360 health facilities in high-burden districts," Motsoaledi said [2].
“"This is a defining moment in our fight against HIV/AIDS."”
The adoption of Lenacapavir signals a strategic shift toward long-acting prophylaxis to increase patient adherence and reduce transmission. By targeting high-burden districts first, South Africa is attempting to stabilize its public health infrastructure after the loss of significant U.S. financial support, moving toward a more sustainable, domestically managed prevention model.
